全文获取类型
收费全文 | 571篇 |
免费 | 62篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 5篇 |
妇产科学 | 1篇 |
基础医学 | 98篇 |
临床医学 | 73篇 |
内科学 | 84篇 |
皮肤病学 | 2篇 |
神经病学 | 111篇 |
特种医学 | 18篇 |
外科学 | 129篇 |
综合类 | 18篇 |
预防医学 | 41篇 |
眼科学 | 6篇 |
药学 | 25篇 |
肿瘤学 | 21篇 |
出版年
2023年 | 16篇 |
2022年 | 8篇 |
2021年 | 39篇 |
2020年 | 17篇 |
2019年 | 31篇 |
2018年 | 32篇 |
2017年 | 19篇 |
2016年 | 16篇 |
2015年 | 17篇 |
2014年 | 22篇 |
2013年 | 22篇 |
2012年 | 38篇 |
2011年 | 38篇 |
2010年 | 21篇 |
2009年 | 21篇 |
2008年 | 26篇 |
2007年 | 24篇 |
2006年 | 25篇 |
2005年 | 21篇 |
2004年 | 20篇 |
2003年 | 15篇 |
2002年 | 17篇 |
2001年 | 6篇 |
1999年 | 3篇 |
1998年 | 5篇 |
1992年 | 4篇 |
1990年 | 3篇 |
1989年 | 3篇 |
1986年 | 3篇 |
1985年 | 3篇 |
1984年 | 4篇 |
1981年 | 3篇 |
1978年 | 3篇 |
1973年 | 5篇 |
1972年 | 5篇 |
1971年 | 5篇 |
1970年 | 4篇 |
1969年 | 3篇 |
1967年 | 4篇 |
1966年 | 3篇 |
1960年 | 2篇 |
1943年 | 2篇 |
1942年 | 2篇 |
1941年 | 2篇 |
1940年 | 3篇 |
1939年 | 2篇 |
1932年 | 2篇 |
1931年 | 2篇 |
1911年 | 4篇 |
1908年 | 2篇 |
排序方式: 共有633条查询结果,搜索用时 31 毫秒
1.
Characterization of gp 50, a major glycoprotein present in rat brain synaptic membranes, with a monoclonal antibody 总被引:4,自引:0,他引:4
Philip W. Beesley Toni Paladino Claude Gravel Richard A. Hawkes James W. Gurd 《Brain research》1987,408(1-2):65-78
Several cell lines secreting monoclonal antibodies (Mabs) against a major forebrain synaptic membrane (SM) glycoprotein, gp 50, have been raised. Western blots show that the Mabs react with a polypeptide doublet of Mrs 49 and 45 kDa. These polypeptides exist solely in a concanavalin A (Con A) binding form. Removal of the Con A receptors by digestion with endo-beta-N-acetylglucosaminidase H (endo H) lowers the Mrs of the glycoprotein doublet to 36.5 and 34 kDa. Western blots of 2D polyacrylamide gels indicate that gp 50 exists in several isoforms. Solid phase radioimmunoassay (RIA) and Western blots of brain subcellular fractions show the antigenic material to be concentrated in the SM fraction, but to be present in much lower amounts in synaptic junctions and postsynaptic densities. Gp 50 appears to be brain specific. Regional distribution studies show that it is present in all brain regions but is two-fold concentrated in cerebellum, brainstem and midbrain compared to forebrain. Immunocytochemical studies of several brain regions show that gp 50-like immunoreactivity is neuron specific and is concentrated in selected neuronal species, particularly granule cells. In both cerebellar and hippocampal granule cells gp 50-like immunoreactivity is localized in the perikarya and primary dendrites. Though immunocytochemistry did not show staining of synaptic regions this may be due to masking of the reactive epitope. The results are discussed in terms of the molecular properties of gp 50 and its subcellular localization in brain tissue. 相似文献
2.
Paul Steinbok Brendon Irvine D. Douglas Cochrane Beverly J. Irwin 《Child's nervous system》1992,8(2):92-96
The long-term functional outcome of 101 children born with meningomyelocele between 1971 and 1981 was assessed, by a combination of retrospective chart review and follow-up assessments. The children had been managed at birth using a process ofnonstandardized selection. Eighty-three of the 101 patients survived after a minimum follow-up of 8.6 years, for a mortality rate of 18%. Forty-four of 83 children (53%) were community ambulators, and this correlated well with the presence of intact quadriceps function. Forty-eight children (58%) attended normal school and were grade-appropriate. Sixty-two of 83 patients (75%) were socially continent of urine, and 71/83 (86%) were socially continent of stool. Hydrocephalus was present in 93 of the 101 children in the study, and 85 children were shunted. Half of the shunted children required a shunt revision in the first year of life, and thereafter the rate of revision decreased, so that after 2 years the risk of revision was approximately 10% per year. 相似文献
3.
4.
5.
Richard J Wong Mei-Ki Chan Zhenkun Yu Ronald A Ghossein Ivan Ngai Prasad S Adusumilli Brendon M Stiles Jatin P Shah Bhuvanesh Singh Yuman Fong 《Clinical cancer research》2004,10(13):4509-4516
PURPOSE: Oncolytic herpes simplex viruses (HSVs) may have significant antitumor effects resulting from the direct lysis of cancer cells. HSVs may also be used to express inserted transgenes to exploit additional therapeutic strategies. The ability of an interleukin (IL)-12-expressing HSV to treat squamous cell carcinoma (SCC) by inhibition of tumor angiogenesis is investigated in this study. EXPERIMENTAL DESIGN: A replication-competent, attenuated, oncolytic HSV carrying the murine IL-12 gene (NV1042), its non-cytokine-carrying analog (NV1023), or saline was used to treat established murine SCC flank tumors by intratumoral injection. The expression of secondary antiangiogenic mediators was measured. Angiogenesis inhibition was assessed by in vivo Matrigel plug assays, flank tumor subdermal vascularity, and in vitro endothelial cell tubule formation assay. RESULTS: Intratumoral injections of NV1042 (2 x 10(7) plaque-forming units) into murine SCC VII flank tumors resulted in smaller tumor volumes as compared with NV1023 or saline. IL-12 and IFN-gamma expression in tumors was 440 and 2.2 pg/mg, respectively, at 24 h after NV1042 injection, but both IL-12 and IFN-gamma were undetectable (<0.2 pg/mg) after NV1023 or saline injections. Expression of two antiangiogenesis mediators, monokine induced by IFN-gamma and IFN-inducible protein 10, was elevated after NV1042 treatment. Matrigel plug assays of NV1042-transfected SCC VII tumor cells demonstrated significantly decreased hemoglobin content and microvessel density as compared with NV1023 and PBS. Excised murine flank tumors treated with NV1042 had decreased subdermal vascularity as compared with NV1023 and PBS. Both splenocytes and IL-12 expression by NV1042 were required for in vitro inhibition of endothelial tubule formation. CONCLUSIONS: IL-12 expression by an oncolytic herpes virus enhances therapy of SCC through antiangiogenic mechanisms. Strategies combining HSV oncolysis with angiogenesis inhibition merit further investigation for potential clinical application. 相似文献
6.
The association between smoking prevalence and eating disorders: a systematic review and meta‐analysis
下载免费PDF全文
![点击此处可从《Addiction (Abingdon, England)》网站下载免费的PDF全文](/ch/ext_images/free.gif)
7.
8.
Joshua C. Black Elnaz Atabakhsh Jaegil Kim Kelly M. Biette Capucine Van Rechem Brendon Ladd Paul d. Burrowes Carlos Donado Hamid Mattoo Benjamin P. Kleinstiver Bing Song Grasiella Andriani J. Keith Joung Othon Iliopoulos Cristina Montagna Shiv Pillai Gad Getz Johnathan R. Whetstine 《Genes & development》2015,29(10):1018-1031
Copy number heterogeneity is a prominent feature within tumors. The molecular basis for this heterogeneity remains poorly characterized. Here, we demonstrate that hypoxia induces transient site-specific copy gains (TSSGs) in primary, nontransformed, and transformed human cells. Hypoxia-driven copy gains are not dependent on HIF1α or HIF2α; however, they are dependent on the KDM4A histone demethylase and are blocked by inhibition of KDM4A with a small molecule or the natural metabolite succinate. Furthermore, this response is conserved at a syntenic region in zebrafish cells. Regions with site-specific copy gain are also enriched for amplifications in hypoxic primary tumors. These tumors exhibited amplification and overexpression of the drug resistance gene CKS1B, which we recapitulated in hypoxic breast cancer cells. Our results demonstrate that hypoxia provides a biological stimulus to create transient site-specific copy alterations that could result in heterogeneity within tumors and cell populations. These findings have major implications in our understanding of copy number heterogeneity and the emergence of drug resistance genes in cancer. 相似文献
9.
Davy Vancampfort James Mugisha Justin Richards Marc De Hert Michel Probst Brendon Stubbs 《Disability and rehabilitation》2018,40(14):1618-1629
Purpose: Understanding barriers and facilitators of physical activity participation in persons living with HIV/AIDS is an essential first step in order to devise effective interventions. The present review provides a systematic quantitative review of the physical activity correlates in people with HIV/AIDS.Methods: Major electronic databases were searched till August 2016. Keywords included “physical activity” or “exercise” or “sports” and “AIDS” or “HIV”.Results: Out of 55 correlates from 45 studies (N?=?13,167; mean age range?=?30.5–58.3?years; 63.2% male) five consistent (i.e., reported in four or more studies) correlates were identified. Lower levels of physical activity were consistently associated with older age (6/10 studies), a lower educational level (6/7), a lower number of CD4 cells/μl (7/11), exposure to antiviral therapy (4/6), and the presence of lipodystrophy (4/4). Other important barriers were the presence of bodily pain (2/2), depression (3/3), and opportunistic infections (3/4). Facilitators were a higher cardiorespiratory fitness level (3/3), a higher self-efficacy (2/2), more perceived benefits (2/2), and a better health motivation (3/3).Conclusions: The current review has elucidated that participation in physical activity by people with HIV/AIDS is associated with a range of complex factors which should be considered in rehabilitation programs.
- Implications for Rehabilitation
Health care professionals should consider HIV-related bodily pain and feelings of depression when assisting people living with HIV in inititiating and maintaining an active lifestyle.
Interventions to improve self-efficacy and motivation, and to help people living with HIV in understanding the benefits of exercise, may encourage greater participation.
10.
The short-term effects of high-dose testosterone on sleep,breathing, and function in older men 总被引:12,自引:0,他引:12
Liu PY Yee B Wishart SM Jimenez M Jung DG Grunstein RR Handelsman DJ 《The Journal of clinical endocrinology and metabolism》2003,88(8):3605-3613
Androgen therapy may precipitate obstructive sleep apnea in men. Despite increasing androgen use in older men, few studies have examined sleep and breathing. Randomized, double-blind, placebo-controlled studies examining effects of testosterone simultaneously on sleep, breathing, and function in older men are not available. Seventeen community-dwelling healthy men over the age of 60 yr were randomized to receive three injections of im testosterone esters at weekly intervals (500 mg, 250 mg, and 250 mg) or matching oil-based placebo and then crossed over to the other treatment after 8 wk of washout. Polysomnography, anthropometry, and physical, mental, and metabolic function were assessed at baseline and after each treatment period. Testosterone treatment reduced total time slept ( approximately 1 h), increased the duration of hypoxemia ( approximately 5 min/night), and disrupted breathing during sleep (total and non-rapid eye movement respiratory disturbance indices both increased by approximately seven events per hour) (all P < 0.05). Despite expected effects on body composition (increase in total and lean mass, reduction in fat mass, P < 0.05, bioimpedance method), upper airway dimensions did not change (acoustic reflectometry). Driving ability (computer simulation), physical activity (accelerometry, Physical Activity Scale in the Elderly), quality of life (SF36, Functional Outcomes of Sleep Questionnaire), mood (Profile of Mood States Questionnaire), sleepiness (Epworth, Stanford scales), and insulin resistance (homeostasis model) also were not changed by treatment. Short-term administration of high-dose testosterone shortens sleep and worsens sleep apnea in older men but did not alter physical, mental, or metabolic function. These changes did not appear to be due to upper airway narrowing. Further study of longer-term lower-dose androgen therapy on sleep and breathing is needed to evaluate its safety in older men. 相似文献